Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Axogen, Inc.

Market Cap 2.38B 2.08B 1.93B 1.8B 3.38B 225B 3.4B 22.84B 8.85B 111B 8.95B 8.76B 385B P/E 2026 *
-115x
P/E 2027 * 291x
Enterprise Value 2.38B 2.08B 1.93B 1.8B 3.38B 225B 3.4B 22.84B 8.85B 111B 8.95B 8.76B 385B EV / Sales 2026 *
8.8x
EV / Sales 2027 * 7.49x
Free-Float
96.59%
Yield 2026 *
-
Yield 2027 * -
1 day+0.61%
1 week+4.28%
Current month+13.58%
1 month+5.04%
3 months+45.68%
6 months+40.21%
Current year+37.00%
1 week 42.25
Extreme 42.25
45.83
1 month 38.08
Extreme 38.075
45.83
Current year 27.54
Extreme 27.54
45.83
1 year 9.34
Extreme 9.345
45.83
3 years 3.45
Extreme 3.45
45.83
5 years 3.45
Extreme 3.45
45.83
10 years 3.45
Extreme 3.45
56.85
Manager TitleAgeSince
Chief Executive Officer 66 2024-08-08
Director of Finance/CFO 42 2025-05-11
Chief Operating Officer 65 2025-01-09
Director TitleAgeSince
Director/Board Member 65 2016-08-31
Director/Board Member 58 2019-05-14
Chairman 70 2024-08-08
Date Insider Type Main position Quantity % Market Cap.
05-07Fiscal year

Director

4,941 0.0095%
05-06Sell

Responsable ventes & marketing

-3,878 0.0075%
05-06Fiscal year

Director

33,150 0.0639%
Change 5-day change 1-year change 3-year change Capi.($)
+0.61%+4.28%+360.84%+392.75% 2.38B
+0.63%-1.01%+16.77%-11.91% 173B
+1.14%-1.04%-20.14%+24.08% 144B
-0.33%-1.63%-9.79%-25.12% 125B
+0.76%-3.45%-55.29%-16.19% 67.32B
+0.78%+2.64%+18.33%-4.95% 50.3B
-0.58%-1.16%-25.96%-32.99% 43.8B
+2.20%-2.14%+9.95%+7.53% 35.89B
-0.44%-0.03%+3.74%+35.01% 34.9B
+0.72%-5.51%-13.59%-21.94% 28.02B
Average +0.55%-1.09%+28.49%+34.63% 70.47B
Weighted average by Cap. +0.54%-1.86%-5.96%-3.84%

Financials

2026 *2027 *
Net sales 271M 236M 219M 205M 384M 25.56B 386M 2.59B 1.01B 12.58B 1.02B 995M 43.68B 318M 278M 257M 241M 451M 30.04B 454M 3.05B 1.18B 14.79B 1.2B 1.17B 51.35B
Net income -21.17M -18.46M -17.1M -16M -30.01M -2B -30.2M -203M -78.6M -983M -79.47M -77.76M -3.41B 8.06M 7.02M 6.51M 6.09M 11.42M 760M 11.49M 77.18M 29.91M 374M 30.24M 29.59M 1.3B
Net Debt - -
Logo Axogen, Inc.
Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel.
Employees
622
Date Price Change Volume
26-06-18 44.84 $ +0.61% 1,295,827
26-06-17 44.57 $ +2.70% 1,800,372
26-06-16 43.40 $ -0.78% 1,982,504
26-06-15 43.74 $ +1.72% 2,883,474
26-06-12 43.00 $ +1.51% 1,553,330
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
44.84USD
Average target price
50.78USD
Spread / Average Target
+13.24%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AXGN Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!